| |
| |
|
| Insider
Information: |
Lundberg Sven Ante |
| Relationship: |
|
| City: |
Cambridge |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
4 |
|
| Direct
Shares |
576,425 |
|
|
Indirect Shares
|
543,112 |
|
|
| Direct
Value |
$29,064,913 |
|
|
|
Indirect Value
|
$28,946,587 |
|
|
| Total
Shares |
1,119,537 |
|
|
| Total
Value |
$58,011,500 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Crispr Therapeutics Ag |
CRSP |
Chief Scientific Officer |
2016-10-24 |
505,217 |
2016-10-24 |
505,617 |
Premium* |
|
|
Merus Nv |
MRUS |
President, CEO & PFO, ... |
2022-11-03 |
40,576 |
2022-11-03 |
37,495 |
Premium* |
|
|
Vor Biopharma Inc. |
VOR |
Director |
2021-02-04 |
29,432 |
|
0 |
Premium* |
|
|
Q32 Bio Inc |
QTTB |
|
2024-03-25 |
1,200 |
|
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
14 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| QTTB |
Q32 Bio Inc |
|
– • – |
2024-03-25 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,200 |
|
- |
|
| MRUS |
Merus Nv |
President, CEO & PFO |
• • – |
2022-11-03 |
4 |
AB |
$14.38 |
$211,431 |
D/D |
14,706 |
40,576 |
0 |
% |
|
| MRUS |
Merus Nv |
President, CEO & PFO |
• • – |
2022-08-22 |
4 |
AB |
$22.92 |
$133,558 |
D/D |
5,826 |
25,870 |
0 |
% |
|
| MRUS |
Merus Nv |
President, CEO & PFO |
• • – |
2022-08-19 |
4 |
AB |
$22.99 |
$16,187 |
D/D |
704 |
20,044 |
0 |
% |
|
| MRUS |
Merus Nv |
President, CEO & PFO |
• • – |
2022-07-12 |
4 |
AB |
$22.97 |
$99,685 |
D/D |
4,340 |
19,340 |
0 |
% |
|
| MRUS |
Merus Nv |
President, CEO & PFO |
• • – |
2021-08-02 |
4 |
OE |
$12.54 |
$200,474 |
D/D |
15,000 |
15,000 |
0 |
- |
|
| MRUS |
Merus Nv |
President, CEO & PFO |
• • – |
2021-03-25 |
4 |
GD |
$0.00 |
$0 |
D/D |
74,000 |
0 |
0 |
- |
|
| MRUS |
Merus Nv |
President, CEO & PFO |
• • – |
2021-03-01 |
4 |
OE |
$12.54 |
$989,867 |
D/D |
74,000 |
74,000 |
0 |
- |
|
| VOR |
Vor Biopharma Inc. |
Director |
– • – |
2021-02-04 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
29,432 |
|
- |
|
| MRUS |
Merus Nv |
President, CEO & PFOOfficer |
• • – |
2020-01-01 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
37,495 |
|
% |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Scientific Officer |
• – – |
2016-10-24 |
4 |
B |
$14.00 |
$5,600 |
I/I |
400 |
505,617 |
1.99 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Scientific Officer |
• – – |
2016-10-24 |
4 |
A |
$0.00 |
$0 |
D/D |
55,217 |
505,217 |
0 |
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Scientific OfficerOffice |
• – – |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
55,217 |
|
- |
|
| CRSP |
Crispr Therapeutics Ag |
Chief Scientific OfficerOffice |
• – – |
2016-10-18 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
450,000 |
|
- |
|
14 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
